Pulmonary Oncology Research Team (New York University (NYU) PORT), Section of Interventional Pulmonology, Division of Pulmonary, Critical Care and Sleep Medicine, NYU Grossman School of Medicine, NYU Langone Health, New York, NY, United States.
Front Immunol. 2023 Aug 21;14:1203539. doi: 10.3389/fimmu.2023.1203539. eCollection 2023.
Despite remarkable advances in tumor response and patient survival in the past decade, systemic immunotherapies for lung cancer result in an objective response in only around half of patients treated. On the basis of this limitation, combination strategies are being investigated to improve response rates. Cryoablation has been proposed as one such technique to induce immunogenic cell death and synergize with systemic immunotherapies, including immune checkpoint inhibitors. Cryoablation has been traditionally delivered percutaneously with imaging guidance although recent technological advances allow for bronchoscopic delivery. Herein, we review the pre-clinical and clinical evidence for the use of cryoablation in non-small cell lung cancer and potential induction of anti-tumor immunity. We highlight ongoing studies involving this approach and propose areas of future investigation.
尽管在过去十年中肿瘤反应和患者生存方面取得了显著进展,但肺癌的全身免疫疗法仅能使大约一半接受治疗的患者产生客观反应。基于这一局限性,正在研究联合策略以提高反应率。冷冻消融术已被提议作为一种诱导免疫原性细胞死亡并与全身免疫疗法(包括免疫检查点抑制剂)协同作用的技术。冷冻消融术传统上是通过影像学引导经皮进行的,尽管最近的技术进步允许支气管内递送。本文综述了冷冻消融术在非小细胞肺癌中的临床前和临床证据及其潜在的抗肿瘤免疫诱导作用。我们强调了涉及该方法的正在进行的研究,并提出了未来的研究领域。